Not available outside of the UK & Ireland.

Application

Cyproheptadine hydrochloride sesquihydrate has been used in:testing anti-inflammatory activity in serotonin receptor (5-HT) induced inflammationthe inhibition of 5-HT in in vivo and in vitro bioassays in crabsthe inhibition of 5-HT in embryo physiological experimentsinhibition of calcitonin gene related peptide (CGRP)

Biochem/physiol Actions

Cyproheptadine hydrochloride sesquihydrate is a serotonin receptor (5-HT2/5-HT1C) antagonist, H1 histamine receptor antagonist and an antipruritic. The inhibition of 5-HT by cyproheptadine improves cognitive function in schizophrenia disorder. Cyproheptadine is effective for treating functional gastrointestinal disorders (FGIDs). Food and Drug Administration (FDA) approved cyproheptadine, has antidepressant and antiplatelet functionality. It may be effective in treating thromboembolic disorders. Cyproheptadine inhibits lysine methyltransferase 7/9 (Set7/9) leading to a decrease in estrogen receptor (ERα) expression and growth arrest in breast cancer cells.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

100 mg in poly bottle

1 g in poly bottle